Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
20.65
67.98
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Chongqing Zhifei Biological Products Co Ltd
Chongqing Zhifei Biological Products Co Ltd
Cash from Financing Activities
Chongqing Zhifei Biological Products Co Ltd
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Cash from Financing Activities
-¥3.5B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-52%
|
CAGR 10-Years
-47%
|
|
|
Beigene Ltd
HKEX:6160
|
Cash from Financing Activities
¥2.6B
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Cash from Financing Activities
¥960.9m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Cash from Financing Activities
-¥893.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-98%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Cash from Financing Activities
-¥1.2B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Cash from Financing Activities
-¥1.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-98%
|
CAGR 10-Years
N/A
|
|
Chongqing Zhifei Biological Products Co Ltd
Glance View
Chongqing Zhifei Biological Products Co., Ltd., founded in 1992, has swiftly ascended to become a key player in the Chinese biopharmaceutical landscape, primarily focusing on the development, manufacturing, and commercialization of vaccines and diagnostic products. The company operates with a vision to address pressing public health challenges, and it has established an impressive portfolio that includes vaccines for diseases like hepatitis, influenza, and COVID-19. With a robust research and development (R&D) foundation, Zhifei has secured multiple partnerships and collaborations, further bolstering its innovation pipeline and expanding its market reach. This strategic positioning within China's burgeoning biopharmaceutical sector highlights the company’s commitment to quality and safety, aligning closely with the growing national emphasis on health and disease prevention. For investors, Zhifei represents not just a stake in a successful vaccine manufacturer, but also an opportunity to participate in a transformative phase of public health management in China and beyond. The company’s recent advancements in vaccine technology and its ability to rapidly pivot in response to global health emergencies—exemplified by its expedited COVID-19 vaccine development—underscore its agility and competitive edge in a high-growth market. As the demand for advanced biological products continues to rise globally, Zhifei’s solid financial foundations, coupled with government support for the biopharmaceutical industry, position it as a compelling investment with the potential for substantial long-term returns. The confluence of innovation, strong governmental backing, and a commitment to improving public health makes Chongqing Zhifei a noteworthy candidate for investors looking to tap into the evolving healthcare landscape.
See Also
What is Chongqing Zhifei Biological Products Co Ltd's Cash from Financing Activities?
Cash from Financing Activities
-3.5B
CNY
Based on the financial report for Jun 30, 2024, Chongqing Zhifei Biological Products Co Ltd's Cash from Financing Activities amounts to -3.5B CNY.
What is Chongqing Zhifei Biological Products Co Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-47%
Over the last year, the Cash from Financing Activities growth was 20%. The average annual Cash from Financing Activities growth rates for Chongqing Zhifei Biological Products Co Ltd have been -1% over the past three years , -52% over the past five years , and -47% over the past ten years .
You don't have any saved screeners yet
